Press Releases
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
March 25, 2019
--Co-inventor of original CTLA4-antibody and immuno-oncology innovator to expand the Company's clinical development expertise--
Read more
Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial
March 21, 2019
Drug Name : docetaxel + ritonavir
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019
March 19, 2019
- Recognition for outstanding and innovative cancer research
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers
February 20, 2019
Sapreme Technologies has been awarded a 6.8 M€ grant by the European Union.
Read more
Modra Pharmaceuticals Expands Management Team and Provides Corporate Update
December 19, 2018
-- Colin Freund has joined as CEO
-- Dr. Edwin De Wit appointed Head of Oncology Development
-- Dr. Alan Barge appointed Chai...
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018
November 13, 2018
Leiden, The Netherlands, November 13, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announce...
Read more
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline
November 02, 2018
Maastricht, The Netherlands, 2nd November 2018 -
Cristal Therapeutics, a clinical stage pharmaceutical company developing targ...
Read more
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
October 24, 2018
Maastricht, The Netherlands, 25th October 2018 - Cristal Therapeutics, a clinical stage pharmaceutical company developing uniqu...
Read more
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting
October 01, 2018
--Two poster presentations highlight INT-1B3's immune-system activation and CD8+ T cell-driven anti-tumor response in addition...
Read more
Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board
September 10, 2018
10th September 2018, Windsor, UK: Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next...
Read more
